Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Dark Forest Capital Management LP

Dark Forest Capital Management LP lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 7.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 134,116 shares of the biopharmaceutical company's stock after selling 10,362 shares during the quarter. Royalty Pharma makes up 0.5% of Dark Forest Capital Management LP's holdings, making the stock its 18th largest holding. Dark Forest Capital Management LP's holdings in Royalty Pharma were worth $3,421,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Swedbank AB lifted its holdings in Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after buying an additional 1,136,800 shares during the period. Geode Capital Management LLC raised its holdings in shares of Royalty Pharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock worth $186,846,000 after buying an additional 46,765 shares during the last quarter. Norges Bank acquired a new stake in Royalty Pharma during the 4th quarter worth about $124,498,000. Charles Schwab Investment Management Inc. increased its holdings in Royalty Pharma by 4.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after buying an additional 130,025 shares during the period. Finally, New South Capital Management Inc. boosted its holdings in shares of Royalty Pharma by 19.9% in the 4th quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company's stock valued at $75,436,000 after acquiring an additional 490,754 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX traded up $0.38 during midday trading on Monday, hitting $32.58. The company had a trading volume of 1,062,884 shares, compared to its average volume of 4,460,183. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The stock has a market cap of $18.78 billion, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The business's 50-day simple moving average is $32.52 and its 200-day simple moving average is $29.45. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.70%. Royalty Pharma's payout ratio is currently 60.69%.

Wall Street Analysts Forecast Growth

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.